Please ensure Javascript is enabled for purposes of website accessibility
top of page

ZYUS Life Sciences Announces Chief Financial Officer Transition

(BUSINESS WIRE)-- ZYUS Life Sciences Inc. ("ZYUS"), a next-generation life sciences company leading scientific research and development in phyto-therapeutics, is announcing a transition of its Chief Financial Officer (“CFO”) position. Effective December 6, 2021, John Hyshka will become acting CFO, replacing current CFO Rob Harding. Mr. Hyshka is an experienced business and finance leader based in Saskatchewan with strong experience establishing and scaling high-growth companies, including in the life sciences space.

Mr. Hyshka, former CFO of Phenomenome Discoveries Inc. (“PDI”) for nearly 15 years brings more than two decades of financial experience in the life sciences industry. Throughout his career, Mr. Hyshka has been successful in leading multi-million-dollar financings for smaller enterprises in the agriculture, medical device, and therapeutics industries.

“We are pleased to welcome John Hyshka as acting CFO,” said Brent Zettl, ZYUS CEO. “Mr. Hyshka’s extensive experience in the life sciences industry and proven track record as a finance leader and in raising capital will be a valuable addition to our leadership team.”

Rob Harding, ZYUS’ current CFO, recently announced his resignation to pursue other opportunities. Mr. Harding leaves the company with the respect and appreciation of the ZYUS team, who extend their thanks and best wishes to Mr. Harding in his future endeavours.

About ZYUS Life Sciences Inc.

ZYUS is a Canadian-based life sciences company focused on the global development and commercialization of innovative cannabinoid-based therapeutics and product candidates. Through clinical research and IP development, we intend to deliver high-quality oils, softgels, topical creams and other cannabinoid-based therapeutics and product candidates to patients worldwide. The ZYUS vision is to elevate cannabinoids as a standard of care and expand the potential of protein-based formulations in pursuit of a transformational impact on patients’ lives. ZYUS: Advancing the Science of Well-Being. Visit

Forward-Looking Information

This news release contains forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of ZYUS to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. These forward-looking statements include, but are not limited to expectations with respect to our business plans, future financial condition, research activities and product lines.

Often, but not always, forward-looking statements can be identified by the use of words such as “expects,” “expected,” “expectation,” “anticipates,” “believes,” “intends,” “estimates,” “predicts,” “continues,” “potential,” “targeted,” “plans,” “possible” and similar expressions, or statements that events, conditions or results “will,” “may,” “could,” “would” or “should” occur or be achieved, or the negative of these terms or other comparable terminology. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements.

Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this press release. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties.

Readers are cautioned that the foregoing list of factors is not exhaustive. The forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date. ZYUS does not assume any obligation to update or revise any forward-looking statements, whether written or oral, that may be made from time to time by us or on our behalf, except as required by applicable law.


Seth Yakatan

Seth Yakatan

Known for solutions that yield results, Seth Yakatan has completed or advised on acquisitions and corporate finance transactions totaling over $3 billion. He is CEO of Katan Associates International—a financial strategy and merchant banking firm specializing in commercialization and asset monetization—especially those within life-science and e-commerce sectors.




bottom of page